Form 8-K GILEAD SCIENCES INC For: Apr 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gilead Sciences (GILD) Receives Positive CHMP Opinion for Marketing Odefsey as HIV-1 Treatment
April 29, 2016 8:11 AM EDTOn 28 April 2016 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Odefsey, intended for the treatment of adults and adolescents infected with human immunodeficiency virus 1 (HIV 1). The applicant for this medicinal product is Gilead Sciences International Ltd. (Nasdaq: GILD).
Odefsey is a fixed-dose combination of three active substances,... More
